Education
About Us
Working with TipRanks
Follow Us
Ventyx Biosciences (VTYX)
NASDAQ:VTYX
VTYX Stock Chart & Stats
$8.19
-$0.21(-8.13%)
At close: 4:00 PM EST
$8.19
-$0.21(-8.13%)
Day’s Range― - ―
52-Week Range$0.78 - $10.55
Previous CloseN/A
Volume4.54M
Average Volume (3M)1.95M
Market Cap
$584.43M
Enterprise Value$39.14M
Total Cash (Recent Filing)$192.64M
Total Debt (Recent Filing)$10.02M
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Mar 19, 2026EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding71,358,635
10 Day Avg. Volume2,111,881
30 Day Avg. Volume1,945,908
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.14
Enterprise Value/Market Cap0.07
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.34
Forecast
1Y Price Target
$13.71Price Target Upside67.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1.66
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionVentyx Biosciences is expanding its Phase 2 trial for VTX2735 to include international cohorts, which could optimize the development timelines and signal confidence in the drug's potential for recurrent pericarditis.
Efficacy ExpectationsThe efficacy of VTX2735 is benchmarked against Rilonacept, a proven treatment in the same therapeutic area, indicating high expectations for its performance.
Strategic AppointmentsVentyx has appointed experienced strategic advisors to its board, potentially providing valuable insights for the company's 2026 strategy.
Bears Say
Market ChallengesColchicine is not universally effective for recurrent pericarditis patients, with 25-30% experiencing recurrence despite guideline therapy, highlighting a challenging market landscape.
Need For Additional TrialsAdditional Phase 2/3 trials in different cardiovascular indications are needed due to the lack of effect on weight loss.
Weight Loss EfficacyNo difference in weight loss was observed across all cohorts, indicating that NLRP3 inhibition is unrelated to weight loss.
Ventyx Biosciences News
VTYX FAQ
What was Ventyx Biosciences’s price range in the past 12 months?
Ventyx Biosciences lowest stock price was $0.78 and its highest was $10.55 in the past 12 months.
What is Ventyx Biosciences’s market cap?
Ventyx Biosciences’s market cap is $584.43M.
When is Ventyx Biosciences’s upcoming earnings report date?
Ventyx Biosciences’s upcoming earnings report date is Mar 19, 2026 which is in 94 days.
How were Ventyx Biosciences’s earnings last quarter?
Ventyx Biosciences released its earnings results on Nov 06, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.449 by $0.129.
Is Ventyx Biosciences overvalued?
According to Wall Street analysts Ventyx Biosciences’s price is currently Undervalued.
Does Ventyx Biosciences pay dividends?
Ventyx Biosciences does not currently pay dividends.
What is Ventyx Biosciences’s EPS estimate?
Ventyx Biosciences’s EPS estimate is -0.37.
How many shares outstanding does Ventyx Biosciences have?
Ventyx Biosciences has 71,358,635 shares outstanding.
What happened to Ventyx Biosciences’s price movement after its last earnings report?
Ventyx Biosciences reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.449. Following the earnings report the stock price went down -5.292%.
Which hedge fund is a major shareholder of Ventyx Biosciences?
Currently, no hedge funds are holding shares in VTYX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ventyx Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.71 (67.40% Upside)
$13.71 (67.40% Upside)
Blogger Sentiment
Bullish
VTYX Sentiment 100%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 5.9%
Last 30 Days ▲ 5.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
235.65%
12-Months-Change
Fundamentals
Return on Equity
-45.35%
Trailing 12-Months
Asset Growth
-29.77%
Trailing 12-Months
Company Description
Ventyx Biosciences
Ventyx Biosciences (VTYX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel, small molecule drugs for the treatment of inflammatory and autoimmune diseases. The company is engaged in the research and development of therapies targeting clinically validated mechanisms, with an emphasis on addressing significant unmet medical needs. Ventyx's core product candidates are designed to modulate key pathways involved in immune system regulation, providing potential new treatments for conditions such as psoriasis, Crohn's disease, and ulcerative colitis.
VTYX Stock 12 Month Forecast
Average Price Target
$13.71
▲(67.40% Upside)
Technical Analysis
Immutep
―
Voyager Therapeutics
―
Silence Therapeutics
―
Foghorn Therapeutics
―
Kyverna Therapeutics, Inc.
―
Ownership Overview
9.73% Insiders
7.77% Mutual Funds
24.16% Other Institutional Investors
53.27% Public Companies and
Individual Investors